Dec. 9 at 3:11 PM
Alcon raised its acquisition offer for STAAR Surgical, amending the merger agreement. The new terms set the purchase price at
$30.75 per share in cash—adding
$150 million in equity value and valuing STAAR at about
$1.6 billion, a 74% premium to its 90-day VWAP and 66% above its August 4 close.
The revision follows STAAR’s “go-shop” period, which ended without higher bids; Alcon had waived its matching rights and breakup fees. The updated deal also cuts executive payouts at STAAR. Alcon will fund the acquisition through short- and long-term credit lines.
Both boards have approved the amended agreement, and STAAR’s board recommends shareholders vote in favor at the December 19, 2025 meeting. Alcon expects the deal to be accretive in its second year, with closing targeted for early 2026 pending regulatory and shareholder approval.
STAAR is known for its EVO ICL lens portfolio, while Alcon is a global eye-care leader.
$ALC $STAA